Why do we need a Public-Private partnership?
Giving patients a voice in drug development
What is a patient preference?
Whose preferences are we collecting?
News from the PREFER project
- Save the date for the DIA/PREFER patient preferences workshop 15-16 June! 2021-04-15
- PREFER webinar 26 April on the value of patient preferences in the medical product life cycle 2021-04-14
- Working together to develop a preference study for treatments to reduce risk of developing RA 2021-04-12
- Do educational tools influence what patients prefer? 2021-03-23
- Patient preference priorities: Questions to answer for patient-centric decision-making 2021-03-15
Clinical case studies
We are running three core PREFER patient preference studies looking at lung cancer, rheumatoid arthritis and neuromuscular disorders. Both academic and industry partners have added studies to the PREFER portfolio that will help us cover different disease areas, methods and research questions.
Want to stay updated on what is going on in PREFER? Follow us on Twitter and YouTube, or subscribe to our newsletter!
We are developing evidence-based recommendations to guide industry, regulatory authorities, HTA bodies, reimbursement agencies, and health care professionals. We start with work to assess methodologies. After that, we test them in clinical case studies. This work will be the basis for the recommendations we make.
Together with stakeholders
PREFER is a public-private partnership with collaboration at every level, making sure we get more than one perspective on everything we do. We have stakeholder partners from Health Technology Assessment bodies and patient organisations. We are also working closely with regulators to ensure recommendations are evidence based, relevant and useful.
Finding out what patients prefer
Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) is a five year public-private research project where academic researchers, HTA, patient organisations, and the pharmaceutical industry work together to find out when, and how patients’ treatment preferences can be used in medical product development.
We are looking forward to sharing our findings with you!
Mats G. Hansson, Uppsala University, Coordinator
Conny Berlin, Novartis, Project Leader
Innovative Medicines Initiative
PREFER is funded by the Innovative Medicines Initiative (IMI): a part of the EU Horizon 2020 Programme.
The academic research in PREFER is funded by Horizon 2020: the EU Framework Programme for Research and Innovation.
The pharmaceutical industry contributes equally to the PREFER project. Industry input to the IMI programme is organised by EFPIA.